Volume 13, Issue 12 1800088
Research Article

Artificial Self‐Sufficient Cytochrome P450 Containing Multiple Auxiliary Proteins Demonstrates Improved Monooxygenase Activity

Tomoaki Haga

Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113‐8656, Japan

Search for more papers by this author
Hidehiko Hirakawa

Corresponding Author

Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113‐8656, Japan

Search for more papers by this author
Teruyuki Nagamune

Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo 113‐8656, Japan

Search for more papers by this author
First published: 24 July 2018
Citations: 3
Present address: Faculty of Life and Environmental Sciences, University of Tsukuba, 1‐1‐1 Tennodai, Tsukuba, Ibaraki 305‐8572, Japan

Abstract

Most bacterial cytochrome P450 monooxygenases (P450s) do not work alone because their active species is generated by two electrons supplied through two separate auxiliary proteins. Artificial “self‐sufficient” P450s, in which one molecule each of the two auxiliary proteins is arranged close to the P450s, have been developed but have not achieved the maximum catalytic turnover numbers of the P450s. In this study, the Pseudomonas putida P450 (P450cam) is assembled with multiple molecules of its auxiliary proteins, putidaredoxin (PdX) and putidaredoxin reductase (PdR), by fusion to a heterotrimeric protein. In the assembled P450cam containing one PdX and one PdR, kinetic analysis reveales that the catalytic cycle of P450cam is suspended twice awaiting the reduction of PdX by PdR. An increase in the number of PdR molecules stimulated the PdX reduction process. Assembly with two PdXs allows one PdX to be reduced during the binding of the other PdX to P450cam for the first electron transfer, eliminating one waiting step. Finally, P450cam assembled with two PdXs and three PdRs showes 92% of the maximum activity of free P450cam. Therefore, assembly with multiple molecules of auxiliary proteins will facilitate in vitro biotechnological applications of the P450s.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.